Hubei Biocause Pharmaceutical to delist from Shenzhen Stock Exchange

Hubei Biocause Pharmaceutical Co. announced its intent to voluntarily delist its A-shares from the Shenzhen Stock Exchange, effective August 25, 2025, following shareholder approval. The decision, approved by the first extraordinary general meeting of 2025, allows the company to transfer its shares to the delisted segment under the management of the National Equities Exchange and Quotations. This move is driven by the company's planned business restructuring and aims to protect the interests of small and medium shareholders.

The company's stock was already under a delisting risk warning from July 8, 2025, due to its inability to disclose its 2024 annual report and Q1 2025 report within the stipulated timeframe. Zhongtai Securities Co. and Grandall Law Firm (Shanghai) provided their opinions, confirming the compliance of the delisting process with relevant regulations.

To protect dissenting shareholders, Hubei Biocause Pharmaceutical will offer a cash option at a price of 1.60 yuan per share. This option, provided by Jingmen Weituo Hongcheng Management Partnership, will be available to all A-share shareholders registered by September 2, 2025, excluding New Life Group, Liu Yiqian, and Wang Wei, as well as shares with existing restrictions. The subscription period for this cash option is from September 15 to September 19, 2025.